Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
個股明細
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
TARA
Protara Therapeutics, Inc.
NASDAQGM
Biotechnology
United States
$3.94
▼
-0.03 (-0.76%)
CLOSED
—
OPEN
$3.93
HIGH
$3.96
LOW
$3.89
PREV CLOSE
$3.97
VOLUME
203.0K
0.37x avg
BID / ASK
2.92 / 5.12
spr 2.200
MARKET CAP
$232.8M
DAY RANGE
$3.89
$3.96
P/E (TTM)
—
Fwd -2.3
EPS (TTM)
-1.36
DIV YIELD
—
52W HIGH
$7.82
-49.6%
52W LOW
$3.02
+30.5%
BETA
1.49
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
AFTER-HOURS
$3.94
+0.00
(+0.00%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
TARA
$3.94
▼
-0.76%
Chart
Valuation
Financials
Peers
News
TARA · K 線技術分析（即時、可互動）
basic
pro
快速分析（約半分鐘，最長 5 分鐘）
K 線圖載入中…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，通常約半分鐘，上游壅塞時最長 5 分鐘。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
一年走勢
RISK-ON
252 BARS · +25.1% YOY
1-year price chart. Started at 3.15, currently 3.94, up 25.1 percent. Range 3.03 to 7.56 over 252 data points.
2025-09-05
$3.15 → $3.94 (+25.1%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
編輯內容 · 非投資建議。
資料來源：Finnhub（報價 / 公司資料 / 新聞 / 同業）＋ Yahoo（統計）＋ SEC EDGAR XBRL（財務 + DCF）。伺服器端數值經 ISR 快取，最長 60 分鐘；報價則在你的瀏覽器裡即時更新。
VALUATION
確定性估值（SEC EDGAR + Finnhub）
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$3.86
WACC Used
+7.0%
Terminal g
+3.5%
判定: strong-sell
· peers $3.86 (-2.0%)
同業:
ELDN
IVVD
RNA
GLSI
ABOS
TNXP
KROS
ORGO
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
多年財務（SEC XBRL）
—
4 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
—
-$57.4M
-$56.4M
-$56.5M
$209.5M
2024-12
—
-$44.6M
-$35.8M
-$35.9M
$181.5M
2023-12
—
-$40.4M
-$37.6M
-$37.6M
$79.0M
2014-12
$2.9M
—
—
—
—
PEERS
同業與產業對照
CALM
10 PEERS · FINNHUB
ELDN
IVVD
RNA
GLSI
ABOS
TNXP
KROS
ORGO
CHRS
950160.KQ
NEWS
近期新聞（過去 14 天）
—
5 HEADLINES · LAST 14 DAYS
Protara Therapeutics: Q2 Earnings Snapshot
Associated Press · 2026-08-11
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
GlobeNewswire · 2026-08-11
What Makes Protara Therapeutics (TARA) a New Buy Stock
Zacks · 2026-07-21
Protara Therapeutics CMO Leonardo Viana Nicacio Resigns
MT Newswires · 2026-06-30
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
PR Newswire · 2026-06-23